[HTML][HTML] Immunomodulators and risk for breakthrough infection after third COVID-19 mRNA vaccine among patients with rheumatoid arthritis: A cohort study
AE Schiff, X Wang, NJ Patel, Y Kawano, EN Kowalski… - medRxiv, 2023 - ncbi.nlm.nih.gov
Objectives: To investigate COVID-19 breakthrough infection after third mRNA vaccine dose
among patients with RA by immunomodulator drug class, and we hypothesized that CD20 …
among patients with RA by immunomodulator drug class, and we hypothesized that CD20 …
COVID‐19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post‐Pandemic …
C Ammitzbøll, MK Thomsen, LE Bartels… - ACR open …, 2024 - Wiley Online Library
Objective Rituximab (RTX)‐treated patients exhibit suboptimal responses to COVID‐19
vaccines. However, existing research primarily involves patients already receiving RTX …
vaccines. However, existing research primarily involves patients already receiving RTX …
Prevalence and Risk Factors of Post-Acute Sequela of COVID-19 in Adults with Systemic Autoimmune Rheumatic Diseases
MS Teles, J Brundage, TPY Chiang, JL Alejo… - The Journal of …, 2024 - jrheum.org
Objective Incidence and manifestations of postacute sequelae of coronavirus disease 2019
(PASC) are poorly defined among immunosuppressed populations. We reported …
(PASC) are poorly defined among immunosuppressed populations. We reported …
Long-COVID in Immunocompromised Adults
MS Teles, J Brundage, TPYC MD, JL Alejo, JJP MD - jrheum.org
Objective. Incidence and manifestations of postacute sequelae of coronavirus disease 2019
(PASC) are poorly defined among immunosuppressed populations. We reported …
(PASC) are poorly defined among immunosuppressed populations. We reported …